Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T-2 relaxometry pilot study
Stephen J Wood, Luca Cocchi, Tina-Marie Proffitt, Mirabel McConchie, Graeme D Jackson, Tsutomu Takahashi, Christos Pantelis, Patrick D McGorry, Gregor E Berger
Psychiatry Research - Neuroimaging | ELSEVIER IRELAND LTD | Published : 2010
Awarded by NHMRC
Awarded by Swiss National Science Foundation
This work was supported by two NH&MRC project grants (ID. 145627; 209062), a NH&MRC program grant (ID: 350241), and the Colonial Foundation, Melbourne, Australia A/Prof Wood is supported by a Clinical Career Development Award from the NH&MRC, and Dr Cocchi by a Swiss National Science Foundation young investigator award (PBLAB3-119622). A Margaret & Walter Lichtenstein Foundation award (University of Basel) supported Dr Berger. These funding sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. None of the authors has a conflict of interest with any manufacturer or distributor of omega-3 fatty acids. The presented data were part of an investigator-initiated Laxdale Ltd (now owned by Amarin Corporation) provided the study medication for free. None of the research centres received any financial support from Laxdale Ltd.